Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹40.68 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹40.68 Cr |
| Fresh Issue | ₹33.94 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹75.00-79.00 per share |
| Discount | Retail: 0.00 |
| NSE Code | ZENITHDRUG |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Managers | Gretex Corporate Services Ltd. |
| Allotment Status |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 1,600 shares and in multiples thereof
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specialising in manufacturing and trading high-quality, affordable medicines, including generic drugs.
The company adheres to WHO-GMP guidelines and has received the ISO 9001:2015 certification from a respected EuroUK certification body, demonstrating its commitment to quality.
The product portfolio of the company includes
The Food & Drugs Administration has approved over 600 products, of which 325 are currently in production.
The company is in the process of setting up a new manufacturing facility in Village Muradpura, Depalpur, Indore, Madhya Pradesh.
The company supplies its products to countries such as Costa Rica in Central America and the Caribbean and Pacific regions, Malawi, Mauritius, Mozambique, Sudan, Tanzania, Bhutan , Cambodia in Southeast Asia, Tajikistan, Liberia, Sierra Leone, and Conakry.
Zenith Drugs Limited specializes in third-party manufacturing, also known as white label manufacturing, for esteemed pharmaceutical companies such as Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, among others.
There are currently 89 employees as of March 31, 2023 - 61 on payroll and 28 on contract.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of Machinery & Equipments for Setting up New Unit | 10.61 |
| 2 | Existing Manufacturing Block Upgradation | 2.11 |
| 3 | Working Capital Requirements | 14.40 |
| 4 | General Corporate Purposes | 8.84 |
| Total | 35.96 |
| Period Ended | 30 Sep 2023 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 112.49 | 97.94 | 68.58 |
| Total Income | 69.48 | 115.70 | 92.67 |
| Profit After Tax | 5.39 | 5.15 | 3.13 |
| NET Worth | 22.65 | 17.24 | 12.09 |
| Reserves and Surplus | 10.65 | 16.84 | 11.69 |
| Total Borrowing | 29.03 | 26.05 | 18.81 |
| Amount in ₹ Crore | |||
| KPI | |
|---|---|
| ROE | 35.13% |
| ROCE | 37.29% |
| Debt / Equity | 1.51% |
| RoNW | 29.88% |
| PAT Margin | 4.50% |
| Price to Book Value | 5.50 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 4.29 | 6.29 |
| P/E (x) | 18.4 | 12.56 |
| Promoter Holding | 100% | 69.98% |
| Market Cap | ₹135.48 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Payment to the Lead Manager | 1.30 |
| 2 | Underwriting Fees | 1.03 |
| 3 | Market Making Fees | 2.14 |
| 4 | Fees payable to Registrar to Issue | 0.03 |
| 5 | Fees to Legal Advisor | 0.02 |
| 6 | Advertisement Expenses | 0.05 |
| 7 | Fees payable to Regulators including Stock Exchange & Depositories | 0.08 |
| 8 | Printing & Distribution Expenses | 0.01 |
| 9 | Marketing & Selling Expenses | 0.03 |
| 10 | Payment to Sponsor Bank | 0.02 |
| 11 | Statutory & Other Reports | 0.02 |
Last Updated on 23-Jul-2026 15:21:53
